文献速递腹部泌尿生殖技术与安全MR

接受钆塞酸增强的肿瘤患者肾源性系统性纤维化风险及中重度肾功能不全患者接受钆塞酸后肾源性系统性纤维化风险估计更新

Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
PubMed 文献 · Abdom Radiol (NY) · 2022-01-07

回顾性分析2011年3月至2020年12月192例确诊肿瘤患者接受钆塞酸增强MRI,其中中度肾功能不全33例、重度1例,未报告肾源性系统性纤维化病例;结合文献更新汇总340例重度肾功能不全或透析患者,肾源性系统性纤维化0例(0/340;95%CI 0%和0.9%)。

要点

  • 192例肿瘤患者接受钆塞酸增强MRI,包括33例中度及1例重度肾功能不全,均未报告肾源性系统性纤维化。
  • 汇总文献更新后340例重度肾功能不全或透析患者接受钆塞酸,肾源性系统性纤维化0例(0/340;95%CI 0%和0.9%)。
  • 近期数据提示肾功能不全患者使用钆塞酸可考虑为低风险。

核心结论

  • 本研究未记录到与钆塞酸使用相关的肾源性系统性纤维化病例,包括中度及重度肾功能不全的肿瘤患者。
  • 近期数据提示肾功能不全患者使用钆塞酸可考虑为低风险。

研究设计与样本

  • 回顾性识别2011年3月至2020年12月期间为治疗计划而行钆塞酸增强MRI的确诊癌症患者。
  • 共纳入192例肿瘤患者,平均年龄65.6 ± 11.8岁,其中女性73例。
  • 检索钆塞酸给药前180天内的血清肌酐值并计算估算肾小球滤过率(eGFR),取距每次MRI检查最近的eGFR值。
  • 将搜索结果与前瞻性维护的肾源性系统性纤维化报告病例登记库链接。
  • 进行更新文献综述,识别重度肾功能不全(eGFR < 30 mL/min/1.73 m2或透析)患者中与钆塞酸给药相关的已发表肾源性系统性纤维化病例,并结合发表数据与本研究结果确定肾源性系统性纤维化的发生率及95%置信区间(CI)。

诊断标准与关键数值

  • 本组192例肿瘤患者平均eGFR为89.6 ± 33.0 mL/min/1.73 m2,其中中度肾功能不全(eGFR 30-60 mL/min/1.73 m2)33例、重度肾功能不全(eGFR < 30 mL/min/1.73 m2)1例,未报告肾源性系统性纤维化病例。
  • 更新文献综述包括本研究结果共识别340例重度肾功能不全或透析患者,肾源性系统性纤维化0例(0/340;95%置信区间0%和0.9%)。

临床应用与阅片要点

  • 原文结论指出,近期数据提示肾功能不全患者使用钆塞酸可考虑为低风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Gadoxetic acid (GA) is a half-biliary excreted gadolinium-based contrast agent (GBCA) administered at lower dose than gadobenic acid with similar ionic structure. Gadobenic acid is considered low-risk for nephrogenic systemic fibrosis (NSF) in patients with impaired renal function; however, safety of GA is unclear. The objective of this study was to determine the incidence of NSF in oncology patients undergoing GA-enhanced MRI and to update the risk estimate of NSF in patients receiving GA with severe renal impairment.

MATERIALS AND METHODS: We retrospectively identified GA-enhanced MRI performed for treatment planning in confirmed cancer patients between March 2011 and December 2020. Serum creatinine values within 180 days of GA administration were retrieved and estimated glomerular filtration rate (eGFR) calculated. The eGFR value nearest to each MRI examination was used. The search result was linked to a prospectively maintained registry of reported cases of NSF. An updated literature review was conducted to identify published cases of NSF related to GA administration in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m2 or on dialysis) and the incidence of NSF with 95% confidence intervals (CI) was determined combining published data with our results.

RESULTS: 192 oncology patients underwent GA-enhanced MRI, mean age was 65.6 ± 11.8 years with 73 women. The mean eGFR was 89.6 ± 33.0 mL/min/1.73 m2. There were 33 patients with moderate (eGFR 30-60 mL/min/1.73 m2) and 1 patient with severe (eGFR < 30 mL/min/1.73 m2) renal impairment. There were no reported cases of NSF. Updated literature review including our results identified 340 patients with severe renal impairment or on dialysis with zero cases of NSF (0/340; 95% confidence intervals 0% and 0.9%).

CONCLUSION: No cases of NSF were documented in this study related to gadoxetic acid use in oncology patients, including those with moderate and severe renal impairment. Recent data indicate use of gadoxetic acid in patients with renal impairment can be considered low-risk.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Gauthier, Macleod, Sathiadoss, et al. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment. Abdom Radiol (NY). 2022. PMID: 34997298. doi:10.1007/s00261-021-03367-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。